Clinical Trials Logo

HIV clinical trials

View clinical trials related to HIV.

Filter by:

NCT ID: NCT02903589 Completed - HIV Clinical Trials

Knowledge Attitudes, Beliefs, and Practices Regarding HIV in Populations Living on the Maroni River

CAPMARONI
Start date: January 2012
Phase: N/A
Study type: Observational

The HIV epidemic flared from 0 to over 1% prevalence in a decade on the Maroni river which lies between French Guiana and Surinameaim of the study is to determine the knowledge, attitudes, behaviours, and practices on HIV in the population living along the French bank of the Maroni border. Descriptive statistics are computed from the tabulation of answers to a structured questionnaire. Multivariate logistic models were computed to determine predictors of key outcomes. These data will help taylor prevention intervention in this very particular area.

NCT ID: NCT02903563 Completed - HIV Clinical Trials

Knowledge Attitudes Beliefs and Practices Relative to HIV Among Sex Workers in French Guiana

CAPProstit
Start date: January 2009
Phase: N/A
Study type: Observational

The aim was to determine the knowledge attitudes, beliefs, and practices regarding HIV in a population of sex workers in French Guiana and in the Brazilian border town of Oiapoque. A standardized questionnaire was administered face to face to sex workers. Analysis of the questionnaires led to descriptive statistics. Multiple logistic regression models were computed to determine the predictors of condom use.

NCT ID: NCT02900599 Completed - HIV Clinical Trials

Predicting Treatment and Care Difficulties Among HIV Infected Patients

PREDIVI
Start date: February 2015
Phase: N/A
Study type: Observational

Much of HIV is related to behaviour: sexual risk taking, late diagnosis, adherence to antiretroviral therapy, follow up, disclosure of one's HIV status. The project aimed to use various psychometric tools to determine if these scores have a predictive value on late testing, treatment succes, quality of follow up, and disclosure of HIV to sex partners. The expected outcomes would be to be able to stratify patients using a behavioural risk score and allocate targeted ressources to improve the quality of care for the most at risk patients.

NCT ID: NCT02896699 Completed - HIV Clinical Trials

Advanced HIV Prevention (PrEP Chicago)

Start date: March 2016
Phase: N/A
Study type: Interventional

This study will evaluate the feasibility of a network intervention to train individuals to disseminate PrEP information and motivate initial PrEP interest and knowledge of PrEP in their social networks.

NCT ID: NCT02895087 Completed - HIV Clinical Trials

Study to Explore Natural Daily Variation and Impact of Stress in HIV Levels

CHRONOS
Start date: March 2015
Phase:
Study type: Observational

Despite advances in AntiRetroviral Therapy (ART) leading to a rapid control of the HIV virus in individuals affected, HIV can persist indefinitely and there is no cure. The HIV virus has been shown to have a unique ability to hide within the human gene inside human cells and in tissues, remaining 'silent' and rapidly reactivate 'waking up" if ART is stopped. There are a number of ways to measure the silent HIV reservoir, including a common research-based laboratory test called Cell-Associated UnSpliced (CA-US) HIV RNA. This is an early marker of the HIV virus waking up. It is often used to test how well new drugs developed to eliminate the silent virus might work. This study is examining whether the diurnal variation (daily rhythm) and/or stress can affect CA-US HIV RNA levels in individuals diagnosed with HIV and receiving ART.

NCT ID: NCT02891135 Completed - HIV Clinical Trials

Simplified Algorithm for Treatment Eligibility

SLATE
Start date: March 6, 2017
Phase: N/A
Study type: Interventional

In its 2015 revision of the global guidelines for HIV care and treatment, the World Health Organization called for initiating lifelong antiretroviral treatment (ART) for all patients testing positive for HIV, regardless of CD4 cell count. As countries adopt the new recommendation, known as "treat all," millions of additional patients are becoming eligible for ART worldwide. In sub-Saharan Africa, where most of these patients are located, studies continue to document high losses of treatment-eligible patients from care before they receive their first dose of antiretroviral medications. Among facility-level reasons for these losses are treatment initiation protocols that require multiple clinic visits and long waiting times before a patient who tests positive for HIV is dispensed an initial supply of medications. Simpler, more efficient, accelerated algorithms for ART initiation will be needed if "treat all" is to realize the benefits expected. Experts have proposed a simplified clinical algorithm to screen patients for eligibility for immediate ART initiation at a patient's first clinic visit, without the use of point-of-care laboratory test technologies. The Simplified Algorithm for Treatment Eligibility (SLATE) uses four screens to assess whether a patient is eligible for same-day treatment initiation: i) symptom report, ii) medical history, iii) brief physical examination; and iv) readiness assessment. SLATE is a pragmatic, individually randomized evaluation to determine the effectiveness of the algorithm in increasing ART initiation among non-pregnant adult patients. Approximately 960 HIV-infected adult patients not yet on ART will be enrolled during a routine clinic visit and randomized to receive the intervention or standard care. Patients in the intervention arm will be administered the SLATE screens; those found eligible under the algorithm will be offered immediate treatment initiation, while those who are not eligible will be referred for standard clinic care. Patients in the standard arm will be referred for ART initiation under standard clinic procedures. All care after the initial visit will be by the clinic under standard of care. If successful, SLATE will offer a standardized approach to collecting and interpreting a minimum set of patient data that will avoid delaying treatment initiation for the majority of patients who are eligible for immediate ART, while deferring initiation in the minority who should not start immediately.

NCT ID: NCT02888678 Completed - HIV Infections Clinical Trials

Evaluation of an Integrated Economic Strengthening and HIV Prevention Program for Vulnerable Youth in South Africa

ASPIRES
Start date: February 2016
Phase: N/A
Study type: Interventional

This study evaluates whether the integration of an Economic Strengthening program with an HIV-prevention education program produce synergistic effects on economic and health outcomes for South African youth ages 14-17 years old.

NCT ID: NCT02888288 Completed - HIV Clinical Trials

Integrating Mental Health Into a HIV Clinic to Improve Outcomes Among Tanzanian Youth

Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate if a group-based mental health intervention called Sauti ya Vijana (The Voice of Youth) designed to address mental health challenges faced by adolescents in Tanzania is acceptable and feasible and if it improves mental health, antiretroviral therapy (ART) adherence, and virologic outcomes among HIV-positive adolescents as compared to youth receiving treatment as usual. Mental health intervention sessions will take place three times a month for approximately four months in groups of eight to ten youth based on age and sex. Caregivers will attend two sessions to support the youth and provide the guardian perspective on caring for HIV-positive adolescents. The investigator hypothesizes the mental health intervention will be acceptable, feasible, and will improve mental health and ART adherence among participating youth and this improvement will be sustained over time.

NCT ID: NCT02887209 Completed - HIV Clinical Trials

A Pragmatic Pilot Study of Cognitive Behavioural Therapy for Insomnia Among People Living With HIV

Start date: September 2016
Phase: N/A
Study type: Interventional

Insomnia is a problem for approximately 75% of people living with HIV, which is much higher than the 6% to 10% of people with insomnia in the general population. It is currently unknown why the rate of insomnia is so high among people living with HIV, and because of this, they are often excluded from clinical trials examining the usefulness of cognitive behavioural therapy for insomnia (CBT-I), which is recommended as the first-line treatment for insomnia. Insomnia is also associated with poorer immune functioning and lower medication adherence. The purpose of this study is to examine whether CBT-I is useful at reducing insomnia among people living with HIV, and to examine whether this counselling is safe to provide to this population. Other purposes are to explore whether reducing insomnia will lead to improved immune functioning and medication adherence, to collect feedback about people's experiences receiving CBT-I, to examine which psychological and behavioural factors are associated with insomnia severity among people living with HIV.

NCT ID: NCT02886624 Completed - HIV Clinical Trials

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

SAHIV
Start date: May 31, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the rate of sustained virological response (SVR) 12 weeks after 8-week oral treatment with grazoprevir 100mg/elbasvir 50mg (MRK-combo) in patients with acute hepatitis C genotype1 or 4.